ScreenerHero

DGX Quest Diagnostics Incorporated Common Stock

NYSE · US · Healthcare · Diagnostics & Research · questdiagnostics.com
231.91USD-0.61%Mkt Cap: 25.75B $P/E: 24.98

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing,…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc Common Stock
$242.11BUSDP/E 35.5
DHR
Danaher Corporation Common Stock
$150.48BUSDP/E 38.2
NTRA
Natera, Inc. - Common Stock
$59.15BUSD
LONN
Lonza Group AG
$45.82BUSDP/E 38.1
A
Agilent Technologies, Inc. Common Stock
$47.30BUSDP/E 33.1
IQV
IQVIA Holdings, Inc. Common Stock
$42.50BUSDP/E 32.2
WAT
Waters Corporation Common Stock
$41.75BUSDP/E 107.4
ILMN
Illumina, Inc. - Common Stock
$41.23BUSDP/E 50.8
IDXX
IDEXX Laboratories, Inc. - Common Stock
$40.89BUSDP/E 36.4
MTD
Mettler-Toledo International, Inc. Common Stock
$29.78BUSDP/E 34.0
LH
Labcorp Holdings Inc. Common Stock
$25.02BUSDP/E 25.5
GH
Guardant Health, Inc. - Common Stock
$23.86BUSD
RVTY
Revvity, Inc. Common Stock
$16.91BUSDP/E 72.5
MEDP
Medpace Holdings, Inc. - Common Stock
$16.73BUSDP/E 35.2
ERF
Eurofins Scientific SE
$14.05BUSDP/E 26.2
CRL
Charles River Laboratories International, Inc. Common Stock
$13.85BUSD
ICLR
ICON plc - Ordinary Shares
$12.50BUSDP/E 249.3
BIM
bioMérieux S.A.
$10.02BUSDP/E 20.0
QGEN
Qiagen N.V. Common Shares
$9.24BUSDP/E 22.7
GRAL
GRAIL, Inc. - Common Stock
$6.40BUSD

Key Statistics

Company
Market Cap25.75B USD
Enterprise Value31.91B USD
Revenue (TTM)11.56B USD
Gross Profit3.67B USD
Net Income (TTM)992.00M USD
Revenue/Share105.09 USD
Last Price231.91 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees46.0K
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)24.98
P/E (Forward)19.35
PEG1.52
EV/EBITDA14.08
EV/Revenue2.76
P/S2.23
P/B3.41
EPS (TTM)9.42
EPS (Forward)12.06
52W Range
171.1878% of range248.84
52W High248.84 USD
52W Low171.18 USD
Profitability
Gross Margin33.21%
Oper. Margin15.25%
EBITDA Margin19.60%
Profit Margin8.99%
ROE13.84%
ROA6.11%
Growth
Revenue Growth10.20%
Earnings Growth15.00%
Cash Flow & Leverage
Operating CF1.89B USD
CapEx (TTM)527.00M USD
FCF Margin7.87%
FCF Yield3.53%
Net Debt5.78B USD
Net Debt/EBITDA2.55
Balance Sheet
Debt/Equity0.92
Current Ratio1.59
Quick Ratio1.28
Book Value/Sh68.33 USD
Cash/Share5.67 USD
Dividends
Fwd Div Rate3.44 USD
Trail. Div Rate3.32 USD
Div. Yield1.47%
5Y Avg Yield1.82%
Payout Ratio26.11%
Ex-Div DateOct 6, 2026
Pay DateOct 21, 2026
Splits
Last Split2:1
Split DateJun 21, 2005
Analyst Consensus
Rating2.1 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)247.73 USD
Upside (mean)+6.8%
Target Range204.00 USD – 265.00 USD
204.00+6.8% to mean265.00
# Analysts15
Ownership
Shares Out.110.37M
Float109.81M
Insiders0.43%
Institutions98.87%
Short Interest
Short Ratio3.9d
Short % Float3.27%
Short % Out.3.26%
Shares Short3.60M
Short (prev mo.)3.32M
Technical
SMA 50237.79 (-2.5%)
SMA 200206.08 (+12.5%)
Beta0.55
S&P 52W Chg14.58%
Avg Vol (30d)1.03M
Avg Vol (10d)1.22M
Technical Indicators
RSI (14)45.3
MACD-0.9102
MACD Signal0.3855
MACD Hist.-1.2957
BB Upper248.98 USD
BB Middle237.63 USD
BB Lower226.27 USD
BB Width9.56%
ATR (14)5.382 USD
Vol Ratio (20d)0.92x